ITOS: iTeos Therapeutics Inc Price to Sales
iTeos Therapeutics (ITOS) operates in the advanced immuno-oncology segment with high growth potential. The price/sales multiple on this GURU.Markets chart helps track the gap between quotes and revenues, where the value of 11.00 represents the current figure. Market capitalization relies on payments from GSK for the joint development of antibodies, while revenues are based on research milestone bonuses and future royalties.
Metric breakdowns and analytics for iTeos (ITOS)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Capital iTeos Therapeutics|ITOS - Long-Term Debt to Equity|Current Liabilities to Capital iTeos Pharma|ITOS - Company Debts|Debts to Net Assets iTeos|ITOS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings iTeos Therapeutics|Intermediate Liquidity Ratio iteostherapeutics.com
- net income and valuation ratios data:
ITOS - Net Profit|Expected Net Income iTeos Therapeutics|ITOS - P/E Multiple|Projected Price to Earnings Ratio iTeos Therapeutics Inc|ITOS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation iTeos|ITOS - Operating profit EBITDA|Net earnings per share (EPS TTM) iTeos Therapeutics|ITOS - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months iteostherapeutics.com|ITOS - Earnings growth in current year|Expected net earnings per share growth next year iTeos Therapeutics
- sales revenue and business income indicators:
Fundamental company analysis:ITOS, iteostherapeutics.com
Analyzing the P/S volatility of iTeos Therapeutics (ITOS), an investor assesses the business's market value relative to its annual turnover, which determines the company's resilience to industry shocks. This ratio compares total capitalization with revenue, reflecting the extent to which the proprietary antibody immuno-oncology platform and the B2B development patent perimeter justify current market expectations compared to sector averages.
Who iTeos Therapeutics competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|IMVT (Immunovant, Inc.) - Market Cap to Revenue|KNSA: Market Cap to Sales Volume|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|Price-to-Revenue Ratio Celldex (CLDX)|AUPH - Price to Sales|Price-to-Revenue Ratio BioCryst BCRX|Price-to-Revenue Coefficient veratx.com (VERA)|DNTH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|TRML: Market Cap to Sales Volume|PGEN (Precigen, Inc.) - P/S Multiple|PHAR: Market Capitalization-to-Revenue Ratio|P/S Multiple NKTR|UPB - Price to Sales|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Capitalization-to-Revenue Ratio IMNM|Gossamer Bio, Inc. - P/S Multiple|KALV - P/S Multiple|Septerna (SEPN) - Price-to-Revenue Ratio|Price-to-Sales Ratio PVLA (Pieris Pharma)|SVRA (Savara Corp) - P/S Multiple|Price to Sales Rigel Corp RIGL|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|P/S Multiple astriatx.com (ATXS)|enGene - Market Cap to Revenue|Market Cap to Sales Volume RAPT (RAPT Therapeutics Inc.)|Aerovate - P/S Multiple|Price-to-Revenue Coefficient Aclaris Therapeutics, Inc ACRS|KYTX: P/S Multiple|Market Cap to Revenue tizianalifesciences.com|Price-to-Revenue Ratio Cabaletta Bio|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|Price-to-Revenue Coefficient Avalo Therapeutics Inc|Eledon Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume AGEN (agenusbio.com)|CLYM - Price-to-Revenue Ratio|Price to Sales Zura Bio Ltd|aTyr (ATYR) - Price-to-Revenue Ratio|ADAG - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ImageneBio|Shattuck Therapeutics - Price-to-Sales Ratio|P/S Multiple EQ|CNTB (connectbiopharm.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|adicetbio.com (ACET) - Price-to-Revenue Ratio|Market Cap to Revenue Celularity|INMB (INmune Bio Corp) - P/S Multiple|P/S Multiple Barinthus Biotherapeutics Corp|Market Cap to Revenue KZR (Kezar Life Sciences)|SABS (sabbiotherapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple AKTX (Akari Therapeutics Plc)|Price-to-Revenue Coefficient Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Revenue Ratio|GeoVax Corp (GOVX) - Market Cap to Revenue|Edesa Biotech, Inc. (EDSA) - Price-to-Revenue Ratio|Market Cap to Revenue ibioinc.com|Market Cap to Revenue CARM|P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Revenue Ratio|P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Price to Sales|Aditxt Corp - P/S Multiple|Price-to-Revenue Coefficient GRI Bio Inc GRI|XRTX (XORTX) - Market Cap to Revenue|HIND: Market Cap to Sales Volume|REVB (Revelation Biosciences) - P/S Multiple|Price to Sales indaptusrx.com INDP|Price-to-Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Price to Sales|Price-to-Revenue Ratio Affimed N.V. AFMD|Price-to-Revenue Coefficient Allakos Inc (ALLK)|HOOK: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IGMS (IGM Biosciences, Inc.)|OCEA (Ocean Biomedical) - Market Cap to Revenue|TCBP: Market Cap to Sales Volume|THRD (Third Harmonic Bio, Inc) - P/S Multiple
